Patients who are less than 18 years old Pregnant/breastfeeding/ planning to become pregnant Type 1 diabetes mellitus Diabetes ketoacidosis Hypersensitivity to semaglutide or any components of this medication Personal or family history of medullary thyroid carcinoma History of multiple endocrine neoplasia syndrome History pancreatitis End stage renal disease (on dialysis) Patients with diabetic retinopathy Patients with a history of anaphylaxis or angioedema Caution in patients: Type 2 diabetic patients that are on insulin or a sulfonylurea- due to increased need for glucose monitoring
Consultation To help you lose weight, we give in-depth consultations to identify the root causes of your concerns and suggest the right plan for you
[14] Beyond mechanical factors, obesity contributes to joint disease through metabolic and inflammatory pathways
However, post hoc and pooled analyses of clinical studies investigating semaglutide in both obesity and T2D have shown that GI AEssuch as nausea, vomiting, and diarrhoeacontribute minimally to overall weight reduction
The most noticeable weight loss tends to happen in months 2 and 3 as your dose increases and your body fully adapts
The semaglutide component is the same molecule at the same doses, so the weight loss outcomes are expected to be comparable
